Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma

Surgery

Volumn 142, Issue 6, 2007, Pages 867-875

  Gonzalez, Ricardo J ^a   Tamm, Eric P ^a   Ng, Chaan ^a   Phan, Alexandria T ^a   Vassilopoulou Sellin, Rena ^a   Perrier, Nancy D ^a   Evans, Douglas B ^a   Lee, Jeffrey E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; HYDROCORTISONE; MITOTANE;

ADRENAL CORTEX CARCINOMA; ADRENALECTOMY; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HORMONE SYNTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MITOTANE; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 36649005347     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2007.09.006     Document Type: Article

References (24)

1. Lee J.E., Berger D.H., El-Naggar A.K., Hickey R.C., Vassilopoulou-Sellin R., Gagel R.F., et al. Surgical management, DNA content, and patient survival in adrenal cortical carcinoma. Surgery 118 (1995) 1090-1098
2. Dackiw A.P.B., Lee J.E., Gagel R.F., and Evans D.B. Adrenal cortical carcinoma. World J Surg 25 (2001) 914-926
3. Shulick R.D., and Brennan M.F. Long term survival after complete resection and repeat resection in patients with adrenal cortical carcinoma. Ann Surg Oncol 6 (1999) 719-726
4. Jensen J.C., Pass H.I., Sindelar W.F., and Norton J.A. Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection versus chemotherapy. Arch Surg 126 (1991) 457-461
5. Cohn K., Gottesman L., and Brennan M. Adrenocortical carcinoma. Surgery 100 (1986) 1170-1177
6. Berruti A., Terzolo M., Pia A., Angeli A., and Dogliotti L. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer 15 (1998) 83 :2194-200
7. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 92 (2000) 205-216
8. Macfarlane D.A. Cancer of the adrenal cortex: the natural history, prognosis and treatment in a study of fifty-five cases. Ann R Coll Surg Engl 23 (1958) 155-165
9. Gonzalez R.J., Shapiro S., Sarlis N., Vassilopoulou-Sellin R., Perrier N.D., Evans D.B., et al. Laparoscopic resection of adrenocortical carcinoma: a cautionary note. Surgery 138 (2005) 1078-1085
10. Abiven G., Coste J., Groussin L., Anract P., Fre'de'rique T., Legmann P., Douset B., et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91 (2006) 2650-2655
11. Barnett Jr. C.C., Varma D.G., El-Naggar A.K., Dackiw A.P., Porter G.A., Pearson A.S., et al. Limitations of size as a criterion in the evaluation of adrenal tumors. Surgery 128 (2000) 973-982
12. Pommier R.F., and Brennan M.F. An eleven-year experience with adrenocortical carcinoma. Surgery 112 (1992) 963-971
13. Crucitti F., Bellantone R., Ferrante A., Boscherini M., and Crucitti P. The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group. Surgery 119 (1996) 161-170
14. Icard P., Chapuis Y., Andreassian B., Bernard A., and Proye C. Adrenal cortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery. Surgery 112 (1992) 972-980
15. Venkatesh S., Hickey R.C., Sellin R.V., Fernandez J.F., and Samaan N.A. Adrenal cortical carcinoma. Cancer 64 (1989) 765-769
16. Luton J.P., Cerdas S., Billaud L., Thomas G., Guilhaume B., Bertagna X., et al. Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322 (1990) 1195-1201
17. Haak H.R., Hermans J., van de Velde C.J., Lentjes E.G., Goslings B.M., Fleuren G.J., et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69 (1994) 947-951
18. Abraham J., Bakke S., Rutt A., Meadows B., Merino M., Alexander R., Schrump D., et al. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist. Cancer 94 (2002) 2333-2343
19. Berruti A., Terzolo M., Sperone P., Pia A., Casa S.D., Gross D.J., Carnaghi C., et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer 12 (2005) 657-666
20. Bonacci R., Gigliotti A., Baudin E., Wion-Barbot N., Emy P., Bonnay M., et al. Cytotoxic therapy with etoposide and cisplatin in advanced adrenocortical carcinoma. Reseau Comete INSERM. Br J Cancer 78 (1998) 546-549
21. Bukowski R.M., Wolfe M., Levine H.S., Crawford D.E., Stephens R.L., Gaynor E., et al. Phase II trial of mitotane and cisplatin in patients with adrenal carcinoma: a Southwest Oncology Group study. J Clin Oncol 11 (1993) 161-165
22. Terzolo M., Angeli A., Fassnacht M., Daffara F., Tauchmanova L., Conton P.A., et al. Adjuvant mitotane treatment for adrenocortical carcinoma. New Engl J Med 356 (2007) 2372-2380
23. Favia G., Lumachi F., and D'Amico D.F. Adrenocortical carcinoma: is prognosis different in nonfunctioning tumors?. Results of surgical treatment in 31 patients. World J Surg 25 (2001) 735-738
24. Vassilopoulou-Sellin R., and Guinee V.F. Mitotane in adrenocortical carcinoma. Br J Cancer 70 (1994) 779